Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
13.74
-0.66 (-4.58%)
At close: Jun 27, 2025, 4:00 PM
13.95
+0.21 (1.53%)
After-hours: Jun 27, 2025, 7:33 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Arcutis Biotherapeutics stock ranges from a low of $15 to a high of $21. The average analyst price target of $18.8 forecasts a 36.83% increase in the stock price over the next year.
Price Target: $18.80 (+36.83%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 23, 2025.
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +45.56% | May 23, 2025 |
Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +45.56% | Apr 9, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 3, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +38.28% | Apr 3, 2025 |
Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +45.56% | Apr 3, 2025 |
Financial Forecast
Revenue This Year
316.72M
from 196.54M
Increased by 61.15%
Revenue Next Year
437.01M
from 316.72M
Increased by 37.98%
EPS This Year
-0.57
from -1.16
EPS Next Year
0.16
from -0.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 343.4M | 476.7M | 764.5M | ||
Avg | 316.7M | 437.0M | 593.3M | ||
Low | 286.2M | 392.0M | 443.5M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 74.7% | 50.5% | 74.9% | ||
Avg | 61.1% | 38.0% | 35.8% | ||
Low | 45.6% | 23.8% | 1.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.37 | 0.42 | 2.82 | ||
Avg | -0.57 | 0.16 | 1.22 | ||
Low | -0.72 | -0.27 | 0.38 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 1,636.9% | ||
Avg | - | - | 648.2% | ||
Low | - | - | 135.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.